Drug payment policy for cancer drugs comes under fire

Why This Topic Matters

The topic matters because it connects Medicare drug payment methodology with billing workflow, patient notification, and carrier policy differences. Providers who bill these drugs need to understand the broader policy landscape and the types of guidance being discussed without relying on assumptions about pricing or coverage.

Article Sections

1. Patients sign ABNs

   Discusses beneficiary notice use, carrier payment policy concerns, and the broader Medicare policy debate surrounding these drugs. Also touches on CMS and congressional attention to the issue.

2. CMS continues internal debate

   Summarizes CMS and MedPAC commentary on the payment policy and its potential impact on drug pricing and program spending.

3. How the policies work

   Explains how carrier policies organize the drugs into pricing groups and references local coverage guidance and quarterly payment-limit changes.